Welcome to our dedicated page for Agilent Technologies SEC filings (Ticker: A), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agilent Technologies’ filings rarely read like a simple story—they combine life-science breakthroughs, diagnostic regulations, and consumables economics in hundreds of pages. If you have ever tried to trace chromatography margins across segments or confirm executive stock sales before a product launch, you know the challenge.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Whether you need the Agilent Technologies quarterly earnings report 10-Q filing to gauge consumables growth or an Agilent Technologies proxy statement executive compensation breakdown to benchmark R&D incentives, our platform delivers concise, plain-English takeaways the moment the document hits EDGAR. Real-time alerts surface Agilent Technologies Form 4 insider transactions so you can monitor management moves without scrolling through PDF tables. Material developments? Our AI tags each Agilent Technologies 8-K material events explained note and links it to prior guidance.
Here’s how professionals use this page:
- Track Agilent Technologies insider trading Form 4 transactions and spot buying or selling trends by lab-equipment executives.
- Compare segment revenue, backlog, and China exposure across successive Agilent Technologies annual report 10-K simplified summaries.
- Dive into cash-flow forecasts with our AI annotations inside every Agilent Technologies earnings report filing analysis.
Stop parsing technical jargon line by line. With Stock Titan you’re understanding Agilent Technologies SEC documents with AI—from real-time Agilent Technologies Form 4 insider transactions to deep-dive 10-K footnotes—in minutes, not days.
Agilent Technologies, Inc. files its annual report describing a global business focused on life sciences, diagnostics and applied markets. The company provides instruments, software, services and consumables that support the entire laboratory workflow, serving pharmaceutical, biopharmaceutical, diagnostics, clinical, academic, government, chemical, food, environmental and forensics customers.
In November 2024 Agilent reorganized into three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, and recast historical segment data to match this structure. Life Sciences and Diagnostics Markets combines liquid chromatography and mass spectrometry platforms with diagnostics, genomics, cell analysis and specialty contract development and manufacturing services, including BIOVECTRA and nucleic acid solutions.
Agilent CrossLab provides services, consumables, software and automation that are largely vendor neutral, while Applied Markets focuses on instruments and software for chemical, energy, advanced materials, food and environmental testing. As of October 31, 2025, Agilent employed approximately 18,100 people worldwide, with major R&D and manufacturing sites across the U.S., Europe and Asia.
Agilent Technologies director reports stock sale. A director of Agilent Technologies, Inc. reported selling 2,600 shares of common stock on 12/01/2025 at a weighted average price of $149.812 per share, with individual sale prices ranging from $149.80 to $149.84. After this transaction, the director beneficially owns 4,973.028 shares of Agilent common stock. This total includes 23.092 shares acquired through the company’s dividend reinvestment plan in transactions exempt under Rule 16a-11, which the director has elected to defer.
Agilent Technologies’ senior vice president reported a routine share transaction related to equity compensation. On 11/26/2025, the executive surrendered 208 shares of Agilent common stock to the company at a price of $154.37 per share to cover tax withholding on vesting restricted stock units, as allowed under Rule 16b-3. After this tax-related share surrender, the reporting person beneficially owned 11,639.0318 shares of Agilent common stock directly.
Agilent Technologies, Inc. reported an insider equity transaction by a Senior Vice President. On 11/26/2025, the executive surrendered 280 shares of common stock to Agilent to satisfy tax liabilities arising from the vesting of restricted stock units, as permitted under Rule 16b-3. The shares were valued at $154.37 each for this tax withholding transaction.
After this event, the executive beneficially owned 26,593.9266 shares of Agilent common stock directly and 2,607.6856 shares indirectly through a spouse. This is an administrative tax-related transaction rather than an open-market purchase or sale.
Agilent Technologies, Inc. reported an insider transaction by its President and CEO, who is also a director. On 11/26/2025, the executive surrendered 1,948 shares of common stock to Agilent at $154.37 per share to cover tax liabilities arising from the vesting of restricted stock units under Rule 16b-3.
After this tax-related share surrender, the executive beneficially owns 66,539 shares of Agilent common stock in direct ownership. This filing reflects a routine administrative transaction to satisfy taxes rather than an open-market sale.
Agilent Technologies, Inc. officer and Senior Vice President reported a routine equity transaction on Form 4. On 11/26/2025, the reporting person surrendered 300 shares of Agilent common stock to the company at a price of $154.37 per share to cover tax liabilities arising from the vesting of restricted stock units under Rule 16b-3. After this tax-related surrender, the reporting person beneficially owned 14,207.2469 shares of Agilent common stock, held directly.
Agilent Technologies executive reports small stock disposition for tax withholding
A Senior Vice President of Agilent Technologies, Inc. reported a routine share disposition related to equity compensation. On 11/26/2025, the executive surrendered 430 shares of Agilent common stock at a reported price of $154.37 per share, coded as an "F" transaction, meaning the shares were withheld to cover taxes on vesting restricted stock units. After this transaction, the executive beneficially owns 14,262 shares of Agilent common stock directly. No derivative securities transactions were reported in this filing.
Agilent Technologies executive Rodney Gonsalves, Vice President and Corporate Controller, reported multiple stock transactions in Agilent Technologies, Inc. common stock. On 11/26/2025, he sold 3,000 shares at a weighted average price of $154.9853 per share, with individual sale prices ranging from $154.98 to $155.05. He also surrendered 119 shares to Agilent to cover tax liabilities related to the vesting of restricted stock units.
That same day, Gonsalves reported several gift-related movements: transfers coded as gifts involving 200 shares connected to the Gonsalves Family Charitable Gift Fund and indirect holdings in the Gonsalves Trust. After these transactions, he directly owned 31,526.6872 shares of Agilent common stock and held 40.192 shares indirectly through the Gonsalves Trust.
Agilent Technologies reported an insider equity transaction by a senior vice president. On 11/26/2025, the executive surrendered 332 shares of Agilent common stock to the company to cover tax liabilities arising from the vesting of restricted stock units, as permitted under Rule 16b-3. The shares were valued at $154.37 each for this tax withholding transaction. After this adjustment, the reporting person directly beneficially owns 12,203.056 shares of Agilent common stock.
Agilent Technologies (A) filed a Form 14411/26/2025
The shares to be sold were acquired over time through employee stock purchase plan (ESPP) purchases made for cash and through restricted stock that vested as compensation between
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
